李瑾瑾 王麗敏 聶磊 趙冬梅 李春玉
關(guān)鍵詞:淫羊藿苷;心纖維化;肺纖維化;肝纖維化;腎纖維化
【中圖分類號(hào)】 R2 【文獻(xiàn)標(biāo)識(shí)碼】 A ? ? ? 【文章編號(hào)】2107-2306(2022)06--01
1.淫羊藿苷概述
淫羊藿的化學(xué)成分豐富多樣,它來(lái)自小檗科、淫羊藿屬植物的干燥莖葉。黃酮類化合物是淫羊藿藥材的化學(xué)基礎(chǔ),淫羊藿苷(Icariin,ICA)是淫羊藿中含量最豐富的黃酮類化合物,被認(rèn)為是淫羊藿的主要生物活性成分。從藥代動(dòng)力學(xué)來(lái)看,淫羊藿次苷II、淫羊藿素和去甲基淫羊藿素是淫羊藿苷在體內(nèi)的主要生物活性代謝物[1]。許多研究表明淫羊藿苷在預(yù)防、改善或減輕多器官、組織的炎癥反應(yīng)和纖維化疾病方面可能是有效的。
2.淫羊藿苷與纖維化疾病
2.1淫羊藿苷與肺纖維化
淫羊藿苷干預(yù)博萊霉素導(dǎo)致的大鼠肺纖維化, 抑制炎癥反應(yīng)、細(xì)胞外膠原沉積,其抗纖維化作用似乎是通過(guò)抑制河馬(Hippo)信號(hào)通路的核心轉(zhuǎn)錄調(diào)節(jié)因子YAP實(shí)現(xiàn)的[2]。對(duì)淫羊藿苷進(jìn)行納米修飾,然后將其用于實(shí)驗(yàn),能顯著抑制肺纖維化大鼠血管生成,且抑制作用與劑量和作用時(shí)間有關(guān)[3]。安云霞等人[4]發(fā)現(xiàn)淫羊藿苷可明顯下調(diào) TGF-β1和α-平滑肌肌動(dòng)蛋白(α-SMA)的表達(dá)水平進(jìn)而延緩肺纖維化的發(fā)展,還能改善肺組織病理?yè)p傷,減輕肺部炎癥反應(yīng)。淫羊藿素是由腸道菌群水解淫羊藿苷形成的苷元。Hua等人[5]的研究表明淫羊藿素具有抗纖維化作用,它可上調(diào)小鼠和人的肺成纖維細(xì)胞中過(guò)氧化物酶體增殖物激活受體γ(PPARγ)的表達(dá),抑制由TGF-β誘導(dǎo)的成纖維細(xì)胞向肌成纖維細(xì)胞分化, 減少膠原和α-SMA含量。
2.2淫羊藿苷與心肌纖維化
糖尿病會(huì)導(dǎo)致各種并發(fā)癥,其中就包括糖尿病心肌?。―CM)。淫羊藿苷治療DCM不僅可降低血糖,抑制心肌鈣內(nèi)流,改善舒張功能障礙和心律失常等功能障礙,還可抑制ECM中膠原的聚集,促進(jìn)ECM的降解,從而改善心肌結(jié)構(gòu)損害,減輕心肌纖維化[6]。Qiao等人[7]檢測(cè)到TGF-β1/Smad信號(hào)介導(dǎo)的纖維連接蛋白和Ⅰ型膠原、Ⅳ型膠原在DCM的心肌中表達(dá)上調(diào),而淫羊藿苷可呈劑量依賴性地下調(diào)纖維連接蛋白和膠原,揭示了ICA可能通過(guò)抑制TGF-β1/Smad信號(hào)通路而抑制心肌細(xì)胞外基質(zhì)的積聚,減少纖維化并改善心功能。依賴于激活A(yù)pelin/SIRT3信號(hào),淫羊藿苷可減輕DCM線粒體功能障礙,保護(hù)心肌,減少細(xì)胞凋亡,Masson染色顯示淫羊藿苷治療可減少心臟纖維化形成[8]。張麗梅等[9]在實(shí)驗(yàn)中,通過(guò)masson染色觀察到淫羊藿苷能減輕大鼠高血壓引起的心肌間質(zhì)纖維化。林小英等[10]的研究證明了淫羊藿苷通過(guò)調(diào)控MMP-9、TIMP-1、MMP-2的表達(dá),減少ECM的積聚,抑制異丙腎上腺素誘導(dǎo)的心肌纖維化。
2.3淫羊藿苷與肝纖維化
研究[11]發(fā)現(xiàn),淫羊藿苷通過(guò)降低膠質(zhì)瘤相關(guān)癌基因1(glioma-associated oncogene 1,GLI1)的表達(dá),抑制肝星狀細(xì)胞中刺猬(Hedgehog)信號(hào)通路的過(guò)度激活及上皮-間質(zhì)轉(zhuǎn)化和膠原沉積,對(duì)四氯化碳誘導(dǎo)的小鼠肝纖維化模型具有保護(hù)作用。Li等人[12]的實(shí)驗(yàn)中,淫羊藿素顯著減輕四氯化碳和膽總管結(jié)扎誘導(dǎo)的肝纖維化,通過(guò)線粒體途徑,誘導(dǎo)活化的HSCs凋亡,減少了活化的HSCs的數(shù)量。炎癥、血管生成和自噬與肝纖維化的發(fā)生和發(fā)展密切相關(guān),淫羊藿苷抑制硫代乙酰胺誘導(dǎo)的大鼠肝纖維化,可能與抑制血管生成和自噬有關(guān)系[13]。
2.4淫羊藿苷與腎纖維化
淫羊藿苷對(duì)實(shí)驗(yàn)性糖尿病腎病早期有保護(hù)作用,它調(diào)節(jié)腎組織TGF-β1和IV型膠原的表達(dá)[14]。Ding等人[15]分析ICA對(duì)糖尿病腎病保護(hù)作用的機(jī)制,發(fā)現(xiàn)ICA可通過(guò)Keap1-Nrf2/HO-1軸增加Sesn2誘導(dǎo)的有絲分裂,抑制NLRP3炎性小體的激活。Li等人[16]將淫羊藿苷處理的人臍帶間充質(zhì)干細(xì)胞用于慢性腎功能衰竭,減輕了慢性腎衰大鼠的纖維化水平,降低了炎癥反應(yīng)和氧化損傷,改善了腎功能。實(shí)驗(yàn)表明[17],ICA在高糖誘導(dǎo)的腎小管上皮細(xì)胞中起保護(hù)作用,它可以抑制miR-122-5p表達(dá)以促進(jìn)FOXP2轉(zhuǎn)錄,從而減輕腎小管上皮細(xì)胞的上皮-間質(zhì)轉(zhuǎn)化(EMT)以及腎損傷。王蒙等發(fā)現(xiàn)[18],淫羊藿苷顯著減輕慢性腎衰竭腎間質(zhì)纖維化,與改善線粒體動(dòng)力學(xué)相關(guān)。研究證明[19],ICA改善慢性腎小管間質(zhì)腎病(CTIN)腎臟病理?yè)p傷,降低腎纖維化相關(guān)基因(TGF-β1、α-SMA和I型膠原)的表達(dá),減輕腎小管間質(zhì)纖維化和細(xì)胞凋亡。
參考文獻(xiàn):
[1]ChenruiLi,QiangLi,QibingMei,et al. Pharmacological effects and pharmacokinetic properties of icariin, the major bioactive component in HerbaEpimedii[J]. Life Sciences,2015,126:57-68.
[2]Du W, Tang Z, Yang F, et al. Icariin attenuates bleomycin-induced pulmonary fibrosis by targeting Hippo/YAP pathway[J]. Biomedicine & Pharmacotherapy, 2021, 143: 112152.
[3]Wang J, Sun Y, Tian X. The Inhibitory Effect of Icariin Nanoparticles on Angiogenesis in Pulmonary Fibrosis[J]. Journal of Nanoscience and Nanotechnology, 2021, 21(11): 5429-5435.
[4]安云霞,張曉菊,汪錚,等.淫羊藿苷對(duì)肺纖維化大鼠模型的影響及其機(jī)制[J].安徽醫(yī)科大學(xué)學(xué)報(bào),2020,55(12):1840-1844.
[5]Hua Q, Huang X, Xie W, et al. PPARγ mediates the anti-pulmonary fibrosis effect of icaritin[J]. Toxicology Letters, 2021, 350: 81-90.
[6]Zhang L, Wang S, Li Y, et al. Cardioprotective effect of icariin against myocardial fibrosis and its molecular mechanism in diabetic cardiomyopathy based on network pharmacology: Role of ICA in DCM[J]. Phytomedicine, 2021, 91: 153607.
[7]Qiao C, Wang H, Song Z, et al. Icariin attenuates diabetic cardiomyopathy and downregulates extracellular matrix proteins in heart tissue of type 2 diabetic rats[J]. Pharmacology, 2020, 105(9-10): 576-585.
[8]Ni T, Lin N, Huang X, et al. Icariin ameliorates diabetic cardiomyopathy through Apelin/Sirt3 Signalling to improve mitochondrial dysfunction[J]. Frontiers in Pharmacology, 2020, 11: 256.
[9]張麗梅,楊競(jìng),李意奇,等.淫羊藿苷抑制TGF-β1/Smad2信號(hào)通路改善壓力超負(fù)荷所致的大鼠心肌纖維化[J].中國(guó)藥理學(xué)通報(bào),2013,29(10):1422-1425.
[10]林小英,任星橋,曾凡群,等.淫羊藿苷通過(guò)調(diào)控α-SMA和MMPs/TIMP的表達(dá)改善異丙腎上腺素所誘導(dǎo)的心肌纖維化[J].中國(guó)藥理學(xué)通報(bào),2021,37(08):1087-1092.
[11]Ye L, Yu Y, Zhao Y. Icariin‐induced miR‐875‐5p attenuates epithelial‐mesenchymal transition by targeting hedgehog signaling in liver fibrosis[J]. Journal of Gastroenterology and Hepatology, 2020, 35(3): 482-491.
[12]Li J, Liu P, Zhang R, et al. Icaritin induces cell death in activated hepatic stellate cells through mitochondrial activated apoptosis and ameliorates the development of liver fibrosis in rats[J]. Journal of ethnopharmacology, 2011, 137(1): 714-723.
[13]Algandaby M M, Breikaa R M, Eid B G, et al. Icariin protects against thioacetamide-induced liver fibrosis in rats: Implication of anti-angiogenic and anti-autophagic properties[J]. Pharmacological Reports, 2017, 69(4): 616-624.
[14]Qi M Y, Liu H R, Su Y, et al. Protective effect of Icariin on the early stage of experimental diabetic nephropathy induced by streptozotocin via modulating transforming growth factor β1 and type IV collagen expression in rats[J]. Journal of ethnopharmacology, 2011, 138(3): 731-736.
[15]Ding X, Zhao H, Qiao C. Icariin Protects Podocytes from NLRP3 Activation by Sesn2-induced Mitophagy through the Keap1-Nrf2/HO-1 Axis in Diabetic nephropathy[J]. Phytomedicine, 2022: 154005.
[16]Li W, Wang L, Chu X, et al. Icariin combined with human umbilical cord mesenchymal stem cells significantly improve the impaired kidney function in chronic renal failure[J]. Molecular and cellular biochemistry, 2017, 428(1): 203-212.
[17]Zang L, Gao F, Huang A, et al. Icariin inhibits epithelial mesenchymal transition of renal tubular epithelial cells via regulating the miR-122-5p/FOXP2 axis in diabetic nephropathy rats[J]. Journal of Pharmacological Sciences, 2022, 148(2): 204-213.
[18]王蒙,王凌晨,馮曉軒,等.淫羊藿苷調(diào)控線粒體動(dòng)力學(xué)改善慢性腎衰竭模型大鼠腎間質(zhì)纖維化[J/OL].中國(guó)中藥雜志:1-9.
[19]Hou L, Lin Z, Xu A, et al. Combined protective effects of icariin and selenomethionine on novel chronic tubulointerstitial nephropathy models in vivo and vitro.[J]. The British journal of nutrition,2021,127(1):31-33.
作者簡(jiǎn)介:李瑾瑾(1998-)女,河南省周口市人,在讀碩士研究生,研究方向:兒科腎臟疾病。
*通訊作者:王麗敏(1964-)女,黑龍江省佳木斯市人,碩士,主任醫(yī)師,教授,研究方向:兒科腎臟疾病